WO2009008414A1 - Ｍｍｐ１３に対する中和活性を有するモノクローナル抗体 - Google Patents

Ｍｍｐ１３に対する中和活性を有するモノクローナル抗体 Download PDF

Info

Publication number
WO2009008414A1
WO2009008414A1 PCT/JP2008/062306 JP2008062306W WO2009008414A1 WO 2009008414 A1 WO2009008414 A1 WO 2009008414A1 JP 2008062306 W JP2008062306 W JP 2008062306W WO 2009008414 A1 WO2009008414 A1 WO 2009008414A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmp13
neutralizing
antibody
monoclonal antibody
activity against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/062306
Other languages
English (en)
French (fr)
Inventor
Shoichi Naito
Junji Onoda
Akira Yamauchi
Yoshito Numata
Junji Kishino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Priority to JP2009522646A priority Critical patent/JP5354680B2/ja
Priority to US12/668,201 priority patent/US8536313B2/en
Priority to EP08790943A priority patent/EP2186894A4/en
Publication of WO2009008414A1 publication Critical patent/WO2009008414A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ＭＭＰ１３と特異的に反応する中和モノクローナル抗体、該抗体を用いたＭＭＰ１３の酵素活性中和方法及び免疫学的測定方法、並びに該抗体を含有した診断薬及び医薬組成物を提供する。 これまでＭＭＰ１３に対する種々の抗体が得られてきたがＭＭＰ１３に対して中和活性を有する抗体を得られていなかった。本発明者等が鋭意検討した結果、ＭＭＰ１３に対して特異性を有する中和抗体を見出して本発明を完成するに至った。
PCT/JP2008/062306 2007-07-10 2008-07-08 Ｍｍｐ１３に対する中和活性を有するモノクローナル抗体 Ceased WO2009008414A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009522646A JP5354680B2 (ja) 2007-07-10 2008-07-08 Ｍｍｐ１３に対する中和活性を有するモノクローナル抗体
US12/668,201 US8536313B2 (en) 2007-07-10 2008-07-08 Monoclonal antibody having neutralizing activity against MMP13
EP08790943A EP2186894A4 (en) 2007-07-10 2008-07-08 MONOCLONAL ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST MMP13

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-180784 2007-07-10
JP2007180784 2007-07-10

Publications (1)

Publication Number Publication Date
WO2009008414A1 true WO2009008414A1 (ja) 2009-01-15

Family

ID=40228584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/062306 Ceased WO2009008414A1 (ja) 2007-07-10 2008-07-08 Ｍｍｐ１３に対する中和活性を有するモノクローナル抗体

Country Status (4)

Country Link
US (1) US8536313B2 (ja)
EP (1) EP2186894A4 (ja)
JP (1) JP5354680B2 (ja)
WO (1) WO2009008414A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541534A (ja) * 2010-10-01 2013-11-14 ラーマン，サルマン 治療および診断用途のためのメトジンシン選択性の触媒クレフト特異的抗体の生成方法
CN110997001A (zh) * 2017-06-02 2020-04-10 默克专利股份有限公司 Mmp13结合免疫球蛋白
JP2020523986A (ja) * 2017-06-02 2020-08-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
JP2021118721A (ja) * 2015-08-28 2021-08-12 イマティクス バイオテクノロジーズ ゲーエムベーハー 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2271668B1 (en) 2008-03-24 2017-12-20 Salman Rahman Adam-15 antibodies and immunogenic peptides
US8710014B2 (en) 2010-10-08 2014-04-29 Proteapex Therapeutics Llc Compositions and methods for inhibition of MMP13:MMP-substrate interactions

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0239747A (ja) 1988-07-29 1990-02-08 Meidensha Corp 時刻情報伝送方式
JPH04504365A (ja) 1990-01-12 1992-08-06 アブジェニックス　インコーポレイテッド 異種抗体の生成
JPH06500233A (ja) 1990-08-29 1994-01-13 ジェンファーム　インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
WO1998029560A1 (fr) 1996-12-26 1998-07-09 Fuji Yakuhin Kogyo Kabushiki Kaisha Anticorps monoclonal contre la collagenase 3 et procede de dosage immunologique utilisant cet anticorps
WO2000008704A1 (en) 1998-08-06 2000-02-17 Hawker Energy Products, Inc. Wound lead acid battery with non-circular cells
WO2007065037A2 (en) * 2005-12-02 2007-06-07 Curagen Corporation Antibodies against mmp-13 (collagenase-3) and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2369498T3 (es) 2003-04-04 2011-12-01 Yeda Research And Development Co., Ltd. Anticuerpos para inhibir la actividad de mmp-2 y mmp-9.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0239747A (ja) 1988-07-29 1990-02-08 Meidensha Corp 時刻情報伝送方式
JPH04504365A (ja) 1990-01-12 1992-08-06 アブジェニックス　インコーポレイテッド 異種抗体の生成
JPH06500233A (ja) 1990-08-29 1994-01-13 ジェンファーム　インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
WO1998029560A1 (fr) 1996-12-26 1998-07-09 Fuji Yakuhin Kogyo Kabushiki Kaisha Anticorps monoclonal contre la collagenase 3 et procede de dosage immunologique utilisant cet anticorps
WO2000008704A1 (en) 1998-08-06 2000-02-17 Hawker Energy Products, Inc. Wound lead acid battery with non-circular cells
WO2007065037A2 (en) * 2005-12-02 2007-06-07 Curagen Corporation Antibodies against mmp-13 (collagenase-3) and uses thereof

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Immunochemistry in Practice", BLACKWELL SCIENTIFIC PUBLICATIONS
"Molecular Cloning: A Laboratory Manual", COLD SPRING HARBOR LABORATORY
"principle of various methods described in enzyme immunoassay", 1987, IGAKU-SHOIN LTD.
J. BIOL. CHEM., vol. 269, 1994, pages 16766 - 16773
J. CLIN. INVEST., vol. 99, no. 7, 1997, pages 1584 - 1545
LEEMAN M.F. ET AL.: "The structure, regulation, and function of human matrix metalloproteinase-13", CRIT. REV. BIOCHEM. MOL. BIOL., vol. 37, no. 3, 2002, pages 149 - 166, XP009138150 *
MASKOS K. ET AL.: "Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2", J. MOL. BIOL., vol. 366, no. 4, 2007, pages 1222 - 1231, XP025680012 *
NATURE GENETICS, vol. 15, 1997, pages 146 - 156
NATURE GENETICS, vol. 7, 1994, pages 13 - 21
NATURE, vol. 368, 1994, pages 856 - 859
NIKKEI, SCIENCE, June 1995 (1995-06-01), pages 40 - 50
OSTEOARTHRITIS AND CARTILAGE, vol. 11, no. 9, 2003, pages 673 - 680
See also references of EP2186894A4

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013541534A (ja) * 2010-10-01 2013-11-14 ラーマン，サルマン 治療および診断用途のためのメトジンシン選択性の触媒クレフト特異的抗体の生成方法
JP2021118721A (ja) * 2015-08-28 2021-08-12 イマティクス バイオテクノロジーズ ゲーエムベーハー 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ
AU2020201896B2 (en) * 2015-08-28 2022-08-25 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
JP7506026B2 (ja) 2015-08-28 2024-06-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 様々ながんの免疫治療で使用するための新規ペプチド、ペプチドおよびスキャフォールド組み合わせ
CN110997001A (zh) * 2017-06-02 2020-04-10 默克专利股份有限公司 Mmp13结合免疫球蛋白
JP2020521804A (ja) * 2017-06-02 2020-07-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｍｍｐ１３結合免疫グロブリン
JP2020523986A (ja) * 2017-06-02 2020-08-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
JP7249961B2 (ja) 2017-06-02 2023-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド
JP2023113141A (ja) * 2017-06-02 2023-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ１３結合免疫グロブリン
US11813307B2 (en) 2017-06-02 2023-11-14 Merck Patent Gmbh Polypeptides binding ADAMTS5, MMP13 and aggrecan
US12129308B2 (en) 2017-06-02 2024-10-29 Merck Patent Gmbh MMP13 binding immunoglobulins
JP7834054B2 (ja) 2017-06-02 2026-03-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ１３結合免疫グロブリン

Also Published As

Publication number Publication date
EP2186894A4 (en) 2010-10-20
US20100330092A1 (en) 2010-12-30
US8536313B2 (en) 2013-09-17
JP5354680B2 (ja) 2013-11-27
EP2186894A1 (en) 2010-05-19
JPWO2009008414A1 (ja) 2010-09-09

Similar Documents

Publication Publication Date Title
AU2018200640B2 (en) Humanization of rabbit antibodies using a universal antibody framework
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2013192550A3 (en) Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
WO2010009987A3 (en) Diagnostic antibody assay
LTC2567976I2 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
WO2009112245A9 (en) Antibody against the csf-1 r
WO2008070344A3 (en) Compositions and methods for binding sphingosine-1-phosphate
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
WO2007011907A3 (en) Alpha-synuclein antibodies and methods related thereto
ATE486610T1 (de) Anti-glypican-3-antikörper
UA102247C2 (ru) Иммунологические анализы активности ботулинического токсина серотипа а
WO2006094192A3 (en) Humanized l243 antibodies
EA200800812A1 (ru) Композиции антитела против cd3
WO2012022982A3 (en) Improved antibodies of the class igg4
UY31502A1 (es) Proceso mejorado para sintetizar 5-cyclopentyl-5-11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-5-ol usando tmeda
NZ614857A (en) Bispecific antibodies and methods for production thereof
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
NZ586357A (en) Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2009113814A3 (ko) 간암 진단용 단백질성 마커
WO2008136774A8 (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
WO2007139815A3 (en) Imaging and therapeutic method using progenitor cells
EP2000541A4 (en) HUMANIZED MONOCLONAL ANTI-CD20 ANTIBODY
WO2012071216A3 (en) Antibodies for tumor gangliosides
WO2007027805A3 (en) Method for generating anti-variable region monoclonal antibodies
WO2009086398A3 (en) Anti-t. cruzi antibodies and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08790943

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009522646

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12668201

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008790943

Country of ref document: EP